Ultragenyx Gains on FDA Priority Review for DTX401

Key Regulatory Milestone Achieved

Ultragenyx Pharmaceutical Inc. saw its shares rise 1.6% after the U.S. Food and Drug Administration accepted its Biologics License Application for DTX401. The FDA granted this application a Priority Review, designating it as a potentially significant advancement in treating Glycogen Storage Disease Type Ia, or GSDIa.

Clinical Data Overview

The application is supported by a comprehensive clinical program involving 52 patients with up to six years of follow-up. Data from the Phase 3 GlucoGene study demonstrated that patients treated with DTX401 had a notable reduction in daily cornstarch intake while maintaining stable blood sugar levels. The treatment was well tolerated and showed an acceptable safety profile.

Market Impact and Future Outlook

The FDA's decision had an immediate positive impact on Ultragenyx's stock. The agency has set a Prescription Drug User Fee Act action date of August 23, 2026. If approved, DTX401 would become the first-ever treatment to address the underlying cause of GSDIa, marking a pivotal moment for patients and the company.

Summary

The FDA's acceptance and Priority Review of DTX401 is a critical step forward for Ultragenyx. Investors and the medical community will now closely watch for the final decision in 2026, which could establish a new standard of care for GSDIa.

FAQ

Q: What is DTX401?
A: DTX401 is an AAV gene therapy developed by Ultragenyx for the treatment of Glycogen Storage Disease Type Ia.

Q: What does FDA Priority Review signify?
A: It indicates the FDA's view that the drug, if approved, would be a significant improvement in the safety or effectiveness of the treatment of a serious condition.

Q: When is the final FDA decision expected?
A: The PDUFA action date is set for August 23, 2026.

Source: Investing.com